EDBI Logo
|  
Flyout Menu

Amaranth Medical Completes MEND-II and RENASCENT Studies and Initiates Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold

Amaranth Medical Completes MEND-II and RENASCENT Studies and Initiates Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold

Related Posts

Can Southeast Asia claim its place in the AI economy?

  • 04 06 2026
  • |
Read More

AlphaSense nearly doubles valuation to $7.5 billion in new funding round

  • 03 06 2026
  • |
Read More

Startup funding reaches $214m in April to May period

  • 03 06 2026
  • |
Read More

Alternative investing’s next phase: tackling portfolio challenges

  • 26 05 2026
  • |
Read More

Notice: Unauthorised use of the EDBI name and branding

  • 26 05 2026
  • |
Read More

Exaforce raises $125M Series B to expand AI-native security operations platform

  • 13 05 2026
  • |
Read More

Join our community!

Subscribe to our quarterly e-Newsletter, The Upside to find out what’s shaping the future industries of Singapore and the region.

Subscribe now

Investing in high-growth technologies that shape the future economic pillars of Singapore since 1991.

About EDBI

Team

Portfolio

News and Insights

Careers

Contact Us

Linkedin Youtube

© 2025 EDBI. All rights reserved.

Notice: Unauthorised use of the EDBI name and branding in Japan. EDBI officers will never solicit from the public or offer incentives for participation in our programmes. Report any incident to [email protected] if you are unsure if something is a scam.
Learn more
This is default text for notification bar
Learn more